FREQUENCIES OF SINGLE-NUCLEOTIDE POLYMORPHISMS
AND HAPLOTYPES OF THE SLCO1B1 GENE IN SELECTED
POPULATIONS OF THE WESTERN BALKANS
Daka Grapci A1, Dimovski AJ2, Kapedanovska A2, Vavlukis M3, Eftimov A2, Matevska
Geshkovska N2, Labachevski N4, Jakjovski K4, Gorani D5, Kedev S3, Mladenovska K2,*
*Corresponding Author: Professor Kristina Mladenovska, Faculty of Pharmacy, Center for Biomolecular Pharmaceutical
Analyses, University “Ss Cyril and Methodius” in Skopje, Blv. “Mother Theresa” 47, 1000 Skopje,
Republic of Macedonia. Tel: +389-2-3126-032. Fax: +389-2-3132-015. E-mail: krml@ff.ukim.edu.mk
page: 5
|
|
REFERENCES
1. Liu J, Long J, Zhang S, Fang X, Luo Y. Polymorphic
variants of SLCO1B1 in neonatal hyperbilirubinemia
in China. Ital J Pediatr. 2013;
39(49): 1-5.
2. Lopez-Lopez E, Martin-Guerrero I, Ballesteros
J, Piñan MA, Garcia-Miguel P, Navajas A, et al.
Polymor- phisms of the SLCO1B1 gene predict
methotrexate-related toxicity in childhood acute
lymphoblastic leukemia. Pediatr Blood Cancer.
2011; 57(4): 612-619.
3. Niemi M, Kivistö KT, Hofmann U, Schwab M,
Eichelbaum M, Fromm MF. Fexofenadine pharmacokin-
etics is associated with a polymorphism
of the SLCO1B1 gene (encoding OATP1B1). Br
J Clin Pharmacol. 2005; 59(5): 602-604.
4. Niemi M, Backman JT, Kajosaari LI, Leathart
JB, Neuvonen M, Daly AK, et al. Polymorphic
organic anion transporting polypeptide 1B1 is a
major determinant of repaglinide pharmacokinetics.
Clin Pharmacol Ther. 2005; 77(6): 468-478.
5. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi
M. Different effects of SLCO1B1 polymorphism on
the phar-macokinetics of atorvastatin and rosuvastatin.
Clin Phar-macol Ther. 2007; 82(7): 726-733.
6. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W,
Lemke CJ, et al. Drug and bile acid transporters
in rosuva statin hepatic uptake: Function, expression
and pharmaco genetics. Gastroenterology.
2006; 130(6): 1793-1806.
7. Yamada A, Maeda K, Kamiyama E, Sugiyama
D, Kondo T, Shiroyanagi Y, et al. Multiple human
isoforms of drug transporters contribute to
the hepatic and renal transport of olmesartan, a
selective antagonist of the angiotensin II AT1-
receptor. Drug Metab Dispos. 2007; 35(12):
2166-2176.
8. Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y,
Keppler D, et al. Vectorial transport of enalapril
by Oatp 1a1/Mrp2 and OATP1B1 and OATP1B3/
MRP2 in rat and human livers. J Pharmacol Exp
Ther. 2006; 318(1): 395-402.
9. Neuvonen PJ, Niemi M, Backman JT. Drug interactions
with lipid-lowering drugs: Mechanisms
and clinical relevance. Clin Pharmacol Ther.
2006; 80(6): 565-581.
10. Vavricka SR, Van Mootfort J, Ha HR, Meier PJ,
Fattinger K. Interactions of ryfamycin Sv and
rifampicin with organic anion uptake systems of
human liver. Hepatology. 2002; 36(1): 164-172.
11. Pasanen MK, Neuvonen PJ, Niemi M. Global
analysis of genetic variation in SLCO1B1. Pharmacogenomics.
2008; 9(1): 19-33.
12. Tirona RG, Leake BF, Merino G, Kim RB.
Poly-morphisms in OATP-C: Identification of
multiple allelic variants associated with altered
transport activity among European- and African-
Americans. J Biol Chem. 2001; 276(38): 35669-
35675.
13. Pasanen MK, Backman JT, Neuvonen PJ, Niemi
M. Frequencies of single nucleotide polymorphisms
and haplotypes of organic anion transporting
polypeptide 1B1 SLCO1B1 gene in a
Finnish population. Eur J Clin Pharmacol. 2006;
62(6): 409-415.
14. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara
H, Otsubo K, et al. Effects of organic anion
transporting polypeptide 1B1 haplotype on
pharmacokinetics of pravastatin, valsartan and
temocapril. Clin Pharmacol Ther. 2006; 79(5):
427-439.
15. Oswald S, Konig J, Lutjohann D, Giessmann T,
Kroemer HK, Rimmbach C, et al. Disposition
of ezetimibe is influenced by polymorphisms of
the hepatic uptake carrier OATP1B1. Pharmacogenet
Genomics. 2008; 18(7): 559-568.
16. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1
polymoprhism and sex affect the pharmacokinetics
of pra-vastatin but not fluvastatin. Clin
Pharmacol Ther. 2006; 80(4): 356-366.
17. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee
JE, et al. Influence of the organic anion-transporting
polypeptide 1B1 (OATP1B1) polymorphisms
on irinotecan – Pharmacoknetics and clinical outcome
of patients with advanced non-small lung
cancer. Lung Cancer. 2008; 59(1): 69-75.
18. SEARCH Collaborative group, Link E, Parish
S, Armitage J, Bowman L, Heath S, Matsuda
F, et al. SLCO 1B1 variants and statin-induced
myopathy – A genomewide study. N Engl J Med.
2008; 359(8): 789-799.
19. Santos PC, Gagliardi ACM, Miname MH, Chacra
AP, Santos RD, Krieger JE, et al. SLCO1B1
haplotypes are not associated with atorvastatininduced
myalgia in Brazilian patients with familial
hypercholesterolemia. Eur J Clin Pharmacol.
2012; 68(3): 273-279.
20. Rodrigues AC, Perin PM, Purim SG, Silbiger
VN, Genvigir FD, Willrich MA, et al. Pharmacogenetics
of OATP transporters reveals that
SLCO1B1 c.388A>G variant is determinant of
increased atorvastatin response. Int J Mol Sci.
2011; 12(9): 5815-5827.
21. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa
M, Chiba K. Functional characterization
of SLCO 1B1 (OATP-C) variants, SLCO1B1*5,
SLCO1B1*15 and SLCO1B1*15+C1007G, by
using transient expression systems of HeLa and
HEK 293 cells. Pharmacogenet Genomics. 2005;
15(7): 513-522.
22. Niemi M, Schaeffeler E, Lang T, Fromm MF,
Neuvonen M, Kyrklund C, et al. High plasma
pravastatin concentrations are associated with
single nucleotide polymorphisms and haplotypes
of organic transporting polypep-tide-C (OATPC,
SLCO1B1). Pharmacogenetics. 2004; 14(7):
429-440.
23. Couvert P, Giral P, Dejager S, Gu J, Huby T,
Chapman MJ, et al. Association between a frequent
allele of the gene encoding OATP1B1 and
enhanced LDL-lowering response to fluvastatin
therapy. Pharmacogenomics. 2008; 9(9): 1217-
1227.
24. Lee E, Ryan S, Birmingham B, Zalikowski J,
March R, Ambrose H, et al. Rosuvastatin pharmacokinetics
and pharmacogenetics in white and
Asian subjects residing in the same environment.
Clin Pharmacol Ther. 2005; 78(4): 330-341.
25. Jada SR, Xiaochen S, Yan LY, Xiaoqiang X,
Lal S, Zhou SF, et al. Pharmacogenetics of SLCO1B1:
Haplotypes, htSNPs and hepatic expression
in three distinct Asian populations. Eur J
Clin Pharmacol. 2007; 63(6): 555-563.
26. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu
J, Sai Y, et al. Genetic polymorphisms of human
organic anion transporters OATP-C (SLC21A6)
and OATP-B (SLC21A9): Allele frequencies in
the Japanese population and functional analysis.
J Pharmacol Exp Ther. 2002; 302(2): 804-813.
27. Giannakopoulou E, Ragia G, Kolovou V, Tavridou
A, Tselepis AD, Elisaf M, et al. No impact of SLCO1B1 521T>C, 388A>G and 411G>A
polymorphisms on response to statin therapy
in the Greek population. Mol Biol Rep. 2014;
41(7): 4631-4638.
28. Santos PC, Soares RA, Nascimento RM, Machado-
Coelho GLL, Mill JG, Krieger JE, et al. SLCO1B1
rs414 9056 polymorphism associated with
statin-induced myopathy is differently distributed
according to ethnicity in the Brazilian general population:
Amerindians as a high risk ethnic group.
BMC Med Genet. 2011; 12(136): 1-6.
29. Xu LY, He YJ, Zhang W, Deng S, Li Q, Zhang
WX, et al. Organic anion transporting polypeptide-
1B1 haplotypes in Chinese patients. Acta
Pharmacologica Sinica. 2007; 28(10): 1693-1697.
30. Daka A, Nestorovska AK, Radivojsa I, Mladenovska
K, Vavlukis M, Dimovski A. Frequency
of organic anion transporting polypeptide 1B1
SLCO1B1 gene variants in populations of patients
treated with atorvastatin. Proceedings of
the 41st European Society of Clinical Pharmacy
Symposium on Clinical Pharmacy, October 29-
31 2012, Barcelona, Spain.
31. Shi YY, He L. SHEsis, a powerful software platform
for analyses of linkage disequilibrium,
haplotype construction, and genetic association
at polymorphism loci. Cell Res. 2005; 15(2):
97-98.
32. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T.
Evidence for inverse effects of OATP-C (SLC21A6)
5 and 1b haplotypes on pravastatin kinetics.
Clin Pharmacol Ther. 2004; 75(5): 415-421.
33. Brunham LR, Lansberg PJ, Zhang L, Miao F,
Carter C, Hovingh GK, et al. Differential effect
of the rs4149056 variant in SLCO1B1 on myopathy
associated with simvastatin and atorvastatin.
Pharmacogenomics J. 2012; 12(3): 233-237.
34. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata
K, Hirota T, et al. Polymorphisms of OATPC
(SLC 21A6) and OAT3 (SLC22A8) genes:
Consequences for pravastatin pharmacokinetics.
Clin Pharmacol Ther. 2003; 73(6): 554-565.
35. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung
HR, et al. Effect of OATP1B1 (SLCO1B1) variant
alleles on the pharmacokinetics of pitavastatin
in healthy volunteers. Clin Pharmacol Ther.
2005; 78(4): 342-350.
36. Mwinyi J, Kopke K, Schaefer M, Roots I, Gerloff
T. Comparison of SLCO1B1 sequence variability
among German, Turkish, and African populations.
Eur J Clin Pharmacol. 2008; 64(3): 257-
266.
37. Hubacek JA, Dlouha D, Adamkova V, Lanska
V, Ceska R, Vrablik M. Possible gene-gender interaction
between the SLCO1B1 polymorphism
and statin treatment efficacy. Neuro Endocrinol
Lett. 2012; 33(Suppl 2): 22-25.
38. Aklillu E, Mugusi S, Ngaimisi E, Hoffmann
MM, König S, Ziesenitz V, et al. Frequency of
the SLCO1B1 388A>G and the 521T>C polymorphism
in Tanzania genotyped by a new
LightCycler®-based method. Eur J Clin Pharmacol.
2011; 67(11): 1139-1145.
39. Yang GP, Yuan H, Tang B, Zhang W, Wang LS,
Huang ZJ, et al. Lack of effect of genetic polymorphisms
of SLCO1B1 on the lipid-lowering
response to pitavastatin in Chinese patients. Acta
Pharmacologica Sinica. 2010; 31(3): 382-386.
40. Lin R, Wang X, Zhou W, Fu W, Wang Y, Huang
W, et al. Association of polymorphisms in the
solute carrier organic anion transporter family
member 1B1 gene with essential hypertension in
the Uyghur population. Ann Hum Genet. 2011;
75(2): 305-311.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
